Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 57852-57-0 Chemical Structure| 57852-57-0

Structure of Idarubicin HCl
CAS No.: 57852-57-0

Chemical Structure| 57852-57-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Idarubicin HCl is a HCl salt form of idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL in a cell-free assay.

Synonyms: 4-Demethoxydaunorubicin hydrochloride; Idarubicin (hydrochloride); NSC 256439

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Idarubicin HCl

CAS No. :57852-57-0
Formula : C26H28ClNO9
M.W : 533.95
SMILES Code : O=C1C2=C(O)C([C@@H](O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C[C@](O)(C(C)=O)C4)=C4C(O)=C2C(C5=C1C=CC=C5)=O.[H]Cl
Synonyms :
4-Demethoxydaunorubicin hydrochloride; Idarubicin (hydrochloride); NSC 256439
MDL No. :MFCD00897212
InChI Key :JVHPTYWUBOQMBP-RVFAQHLVSA-N
Pubchem ID :636362

Safety of Idarubicin HCl

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H300-H351-H360
Precautionary Statements:P201-P280-P308+P313
Class:6.1
UN#:2811
Packing Group:

Related Pathways of Idarubicin HCl

DNA

Isoform Comparison

Biological Activity

Target
  • Topo II

    Topo II (MCF-7 cells), IC50:3.3 ng/mL

In Vitro:

Cell Line
Concentration Treated Time Description References
K562 wildtype cells 10 μM 2 hours To evaluate the cytotoxicity of Idarubicin on wildtype K562 cells, results showed that Idarubicin has high cytotoxicity on wildtype cells. PMC11345819
K562 cells overexpressing ABCB1 10 μM 2 hours To evaluate the cytotoxicity of Idarubicin on ABCB1-overexpressing K562 cells, results showed that Idarubicin still has high cytotoxicity on ABCB1-overexpressing cells. PMC11345819
K562 cells overexpressing ABCG2 10 μM 2 hours To evaluate the cytotoxicity of Idarubicin on ABCG2-overexpressing K562 cells, results showed that Idarubicin has lower cytotoxicity on ABCG2-overexpressing cells. PMC11345819
LNCaP/ABI cells 1 μM 24 hours To screen for drugs that overcome abiraterone resistance, Idarubicin was identified as a candidate drug that inhibits the growth of abiraterone-resistant prostate cancer cells PMC9744908
U937 cells 0.2, 0.4, 0.8, 1.6 μmol/L 2 days To evaluate the effect of sequential combination of DAC and Idarubicin on AML cell proliferation, the results showed synergistic effect PMC4082426
HEL cells 0.02, 0.04, 0.08, 0.16 μmol/L 2 days To evaluate the effect of sequential combination of DAC and Idarubicin on AML cell proliferation, the results showed synergistic effect PMC4082426
SKM-1 cells 2, 4, 8, 16 μmol/L 3 days To evaluate the effect of sequential combination of DAC and Idarubicin on AML cell proliferation, the results showed synergistic effect PMC4082426
AML patient cells 2, 4, 8, 16 μmol/L 2 days To evaluate the effect of sequential combination of DAC and Idarubicin on AML cell proliferation, the results showed synergistic effect PMC4082426

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Subcutaneous xenograft model Intraperitoneal injection 10 mg/kg single dose To evaluate the in vivo antitumor effect of Idarubicin on abiraterone-resistant prostate cancer, Idarubicin significantly inhibited tumor growth and prolonged mouse survival PMC9744908
NOD/SCID mice Subcutaneous AML model Intraperitoneal injection 0.25 mg/kg Twice weekly, tumor growth was monitored To evaluate the effect of sequential combination of DAC and Idarubicin on tumor growth in subcutaneous AML mouse model, the results showed significant tumor growth inhibition PMC4082426

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.87mL

0.37mL

0.19mL

9.36mL

1.87mL

0.94mL

18.73mL

3.75mL

1.87mL

References

 

Historical Records

Categories